Real-life ruxolitinib experience in intermediate-risk myelofibrosis

BACKGROUND: In this retrospective cohort of patients with primary, post-polycythemia vera, or post-essential thrombocythemia myelofibrosis, 57 patients with MF who received ruxolitinib for MF-related symptoms or symptomatic splenomegaly were evaluated. METHODS: The median age of the patients in this...

Descripción completa

Detalles Bibliográficos
Autores principales: Arikan, Fatma, Toptas, Tayfur, Atagunduz, Isik Kaygusuz, Ercan, Tarik, Oruc, Ozen, Yilmaz, Fergun, Tuglular, Tulin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721444/
https://www.ncbi.nlm.nih.gov/pubmed/34916339
http://dx.doi.org/10.5045/br.2021.2021101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721444/
https://www.ncbi.nlm.nih.gov/pubmed/34916339
http://dx.doi.org/10.5045/br.2021.2021101

Ejemplares similares